For women’s health, Organon changed the financial language

More than two years after Merck & Co. spun Organon into an independent enterprise — and one of the only pharmas with a focus on women’s health — it’s buckled down on improving access to a ready-made portfolio while meeting unmet needs in the space.The “why” of this mission is easy to answer — scores of women’s health conditions have long been neglected by pharma R&D. It’s the “how” that’s been tougher to sort out. But using sustainable financing models, Organon has found a way.